Showing 1 - 11 of 11 trials – Showing only trials currently accepting patients

• Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  Stanford is currently accepting patients for this trial.

• Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders

  Stanford is currently accepting patients for this trial.

• Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

  Stanford is currently accepting patients for this trial.

• Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

  Stanford is currently accepting patients for this trial.

• Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

  Stanford is currently accepting patients for this trial.

• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  Stanford is currently accepting patients for this trial.

• Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  Stanford is currently accepting patients for this trial.

• Home Away From Home - Quality of Life Surveys

  Stanford is currently accepting patients for this trial.

• A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  Stanford is currently accepting patients for this trial.

• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  Stanford is currently accepting patients for this trial.

• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

  Stanford is currently accepting patients for this trial.